Polaris Group Subsidiaries
Polaris Pharmaceuticals, Inc. is a Delaware corporation based in San Diego and founded in 2006.
As a member of the Polaris Group companies, Polaris is responsible for the research and development required to maintain a robust pipeline and for conducting clinical studies in North America and Europe.
Polaris Group Affiliates
TDW Pharmaceuticals, Inc. is a Taiwan-based company founded in 2003.
TDW is currently developing ADI-PEG 20 for the treatment of hepatocellular carcinoma (HCC) in Taiwan. The company completed a randomized Phase II study for subjects with unresectable HCC. These study results confirmed the safety and efficacy of ADI-PEG 20 as a treatment for HCC. TDW is now working with the Polaris Group on a Phase III, multi-national, multi-center study for HCC.
As an affiliate of the Polaris Group companies, TDW is responsible for conducting clinical studies in the Asian-Pacific region.
DesigneRx Pharmaceuticals, Inc. was founded in 2002 in California.
The company built a cGMP facility for biologics in 2004 and began to provide ADI-PEG 20 for several early stage clinical studies in Europe, the USA and Taiwan in 2005.
As an affiliate of the Polaris Group companies, DesigneRx is responsible for production of study drugs for all Polaris clinical studies.
DesigneRx (Shanghai) was founded in 2007 in Shanghai, China.
The company constructed an animal research facility and a cell culture laboratory in 2008.
As an affiliate of the Polaris Group companies, DesigneRx (Shanghai) is responsible for the pre-clinical pharmacokinetic analysis, in vitro testing of new drug candidates in selected tumor cell lines and in vivo testing of new drug candidates in selected xenograft models.